Tag:

Bexsero

Latest Headlines

Latest Headlines

Novartis' Bexsero wins FDA 'breakthrough' status

A couple of weeks ago, the FDA handed Pfizer's meningitis B candidate its breakthrough therapy designation, setting it up for a race to market with Novartis' Bexsero. Now, the Swiss company's jab has one to match, meaning it may not be long before it can start contributing some much-needed sales to Novartis' vaccines unit.

Novartis' Bexsero wins U.K. recommendation in government U-turn

Going into 2014 Novartis said this was the year Bexsero, the great hope of its struggling vaccine unit, would begin to generate significant sales. Exactly how significant depends on whether governments agree to pay for the vaccine, and in this regard Novartis received a big boost this week. Britain could begin vaccinating all babies with Bexsero as early as this summer.

Novartis' vaccine unit gets a badly needed booster from the U.K.

The U.K.'s Joint Committee on Vaccination and Immunization (JCVI) is revising its stance on Novartis' meningitis B vaccine Bexsero. The jab, originally left off Britain's routine vaccination schedule, has gained the JCVI's nod, supplying a needed boost for the Swiss company's flailing vaccine unit.

Novartis to submit Bexsero to FDA in Q2

The use of Bexsero to quell meningitis B outbreaks at two U.S. universities has given Novartis safety data from 14,000 people, but also convinced the Swiss drugmaker it cannot keep shipping the vaccine under investigational use. Novartis has now outlined its plan to make Bexsero more widely available, starting with a submission to FDA in the second quarter.

Novartis' Bexsero sparks debate about transatlantic vaccine approvals

While the meningitis B outbreak has died down, the debate it stirred up continues. This week researchers at the Manhattan Institute weighed in with their opinion: If a vaccine is good enough for Europe, it is good enough for the U.S..

Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls

Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.

Students in California are still waiting for Novartis' Bexsero to arrive

The meningitis B outbreak at the University of California, Santa Barbara, has slowed for now, with no new cases on the campus since November. However, authorities still view the bacteria as a threat and are trying to get clearance to use Novartis' Bexsero. When that will happen is unclear, though.

California calls for unapproved Bexsero to stop its meningitis outbreak

Californian health officials have asked for permission to use Novartis' unapproved meningitis B vaccine Bexsero to control an outbreak at a college.

Novartis awaits pivotal Bexsero decisions in Canada and Europe

Bexsero has always carried high expectations at Novartis. As the vaccine unit posted loss after loss in recent years, Novartis pitched the meningitis B vaccine to investors as the product that would usher in an era of consistent profitability. This is yet to happen, but the slow rollout of the vaccine continues.

CDC considers expanding use of Bexsero as meningitis outbreak spreads

Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.